Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun 3;34(26):2939-2947.
doi: 10.1016/j.vaccine.2016.03.111. Epub 2016 Apr 19.

The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps

Sami L Gottlieb  1 , Carolyn D Deal  2 , Birgitte Giersing  3 , Helen Rees  4 , Gail Bolan  5 , Christine Johnston  6 , Peter Timms  7 , Scott D Gray-Owen  8 , Ann E Jerse  9 , Caroline E Cameron  10 , Vasee S Moorthy  3 , James Kiarie  3 , Nathalie Broutet  3
Affiliations
Review

The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps

Sami L Gottlieb et al. Vaccine. .

Abstract

In 2014, the World Health Organization, the US National Institutes of Health, and global technical partners published a comprehensive roadmap for development of new vaccines against sexually transmitted infections (STIs). Since its publication, progress has been made in several roadmap activities: obtaining better epidemiologic data to establish the public health rationale for STI vaccines, modeling the theoretical impact of future vaccines, advancing basic science research, defining preferred product characteristics for first-generation vaccines, and encouraging investment in STI vaccine development. This article reviews these overarching roadmap activities, provides updates on research and development of individual vaccines against herpes simplex virus, Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum, and discusses important next steps to advance the global roadmap for STI vaccine development.

Keywords: Roadmap; STI vaccine development; Sexually transmitted infections; Vaccines.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest statement: Drs. Gottlieb, Deal, Giersing, Rees, Bolan, Timms, Gray-Owen, Jerse, Cameron, Moorthy, Kiarie, and Broutet report no potential conflicts of interest. Dr. Johnston has conducted research at the University of Washington sponsored by the following companies as a principal or co-investigator: Agenus, Genocea, Vical, Gilead, AiCuris, and Sanofi.

Figures

Fig. 1.
Fig. 1.
Global and regional estimates of the number of new cases of 4 curable STIs (chlamydia, gonorrhea, syphilis, and trichomoniasis) among 15–49 year-olds in 2012. Global total = 357 million incident infections [1].
Fig. 2.
Fig. 2.
Global and regional estimates of the number of prevalent cases of HSV-2 infection among 15–49 year-olds in 2012. Global total = 417 million prevalent infections [2].
Fig. 3.
Fig. 3.
Elements of the comprehensive vaccine business case. PPCs = preferred product characteristics.
Fig. 4.
Fig. 4.
Current status of the development pathway of STI vaccines.
See this image and copyright information in PMC

References

    1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya N, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLOS ONE 2015;10:e0143304. - PMC - PubMed
    1. Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLOS ONE 2015;10:e114989. - PMC - PubMed
    1. Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Gottlieb SL, et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLOS ONE 2015;10:e0140765. - PMC - PubMed
    1. Newman L, Kamb M, Hawkes S, Gomez G, Say L, Seuc A, et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLOS Med 2013;10:e1001396. - PMC - PubMed
    1. GLOBOCAN: International Agency for Research on Cancer. Cervical cancer: estimated incidence, mortality and prevalence worldwide in 2012; 2012. http://globocan.iarc.fr/Pages/factsheetscancer.aspx [accessed 10.03.16].

MeSH terms